Mario Gaudino, MD, PhD, spoke to Cardiovascular Business about minimally invasive procedures, the growing interest in clinical trials and other key trends in the world of cardiac surgery.

PPMI after aortic valve surgery is known to increase certain risks for patients, but its impact after mitral valve procedures is unclear. A team of researchers aimed to learn more, tracking data from more than 4,500 patients.

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

"The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

Researchers believe a new robotic TEE system could improve the long-term health of interventional echocardiographers in addition to several other key benefits.

While LVOT modification does make these procedures longer, it can help high-risk patients avoid systolic anterior motion.